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Access to innovative medicines 
 
One current bottleneck concerns the access and 
reimbursement of innovative medicines, related to 
uncertainty about effectiveness and safety, but 
primarily conceived high prices. Moreover, there is 
an unmet medical and societal need for access of 
innovative medicines in the developing countries 
(Inotai and Kaló, 2019). Contemporaneous, all 
parties involved in the medicine pathway are facing 
their own challenges. Common ground to overcome 
the differences and fulfill the needs of all parti-
cipants in one integrated healthcare system may be 
the design of Managed Entry Agreements (MEAs).  
 
Managed Entry Agreements  
 
A MEA is an innovative tool engaging health 
authorities and pharma-industry to reach agreements 
towards facilitating the access to innovative 
medicines and structure price negotiations as well. 
Using various instruments, MEAs often ensure 
minimalization of uncertainty from economic 
evaluations and budget impact analyses accounting 
for the real-world evidence (RWE) (Ferrario et al., 
2017; Kanavos et al., 2017). Notably, the recent 
decade has shown a strong trend of including RWE 
in the assessments, next to obviously still the data 
from trials. Furthermore, there is fast change and 
wide range of reimbursement policies across Europe. 
In conjunction with conventional HTA, national 
authorities are using various contracting schemes, 
such as price cuts, reference price policies, budget 
caps, patient co-payments, payment by result, 
coverage with evidence development, price-volume 
agreements, discount agreements, agreements for 
free doses, payback agreements and conditional 
reimbursement (Wenzl and Chapman, 2019). 
Notably, all these contracts exemplify MEAs.  
 
Types of MEA 
MEAs can be financial- or health outcome-based 
agreements. The latter might be based on 
performance or evidence development. Financial 
agreements are increasing the financial certainty 
through price based on volume or market share, total 
spend, or a combination of both at population level, 
free treatments and fixed price or cost-sharing at the 
patient level. Health outcome-based agreements are 
supposed to cope with the uncertainty in the 
outcomes with risk-sharing, can be related to 
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adherence, cover performance payment at population 
level or additional patient services and ensure shared 
accountability or evidence-based outcomes at the 
patient level. Finally, a third type of MEAs exist, 
sharing characteristics of both types previously 
mentioned. (Wenzl and Chapman, 2019) 
 
MEA in practice 
Globally seen up to 2018, Europe is a leader 
with more than 60% of MEAs submissions. Within 
Europe, Italy dominates with 88 innovative 
contracting submissions, followed by the UK (70), 
and Sweden (68). (Deloitte, 2019) When MEA-type 
is concerned, preferred use of financial-based 
agreements is noted in Belgium, Lithuania, England, 
Portugal, Malta, Cyprus, while the performance-
based ones were more common in the Netherlands, 
Sweden and Czech Republic. (Kanavos et al., 2017)  
The latter are concerned with coverage-under-
evidence-development. Notably, monitoring 
processes are not transparent and primarily focused 
on effectiveness, which demonstrates need for future 
attention on safety as well. Obviously, the field of 
MEAs is an extremely dynamic field, for example, 
the Netherlands recently moved away from 
performance to price negotiations. (Wenzl and 
Chapman, 2019) The utilization of MEAs in Central 
and Eastern Europe is mostly dominated by 
discounts (73%), paybacks (14%), price-volume 
agreements (5%), free doses, and bundle agreements 
(< 5%). (Ferrario et al., 2017) These agreements are 
mainly focusing on oncology and diabetes 
medicines. Even though the implementation and 
utilization trend is increasing, there is a lack of 
transparency noted in these countries. (Ferrario et 
al., 2017; Inotai and Kaló, 2019).  
 
Future implications & conclusion 
 
Access to innovative medicines, personalized 
treatments and improved medicine performance, 
affordability within the budget and effectiveness 
uncertainty, as well as impetus for further research 
into innovative medicines, all reflect advantages 
justifying the use of MEAs. Yet, further work on 
MEAs is required. Notably, further development in 
the area of transparency in pricing and costing are 
needed as well as solutions for medicine access after 
agreement expiration, simplifying and setting a 
standard agreement framework, improved patient 
and data monitoring mechanisms with attention on 
safety outcomes, sharing information from 
performance-based MEAs and developing 
methodologies towards measuring societal value for 
continues use of gathered data in HTA. (Kanavos et 
al., 2017; Wenzl and Chapman, 2019)  
In conclusion, increased and systematic use of 
HTA in correlation with MEA facilitates the access 
to innovative medicines and represents a good 
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